

## Lifeline Drugs & Pharma Limited

Regd Office : F/3, Shah Arcade, Wing- C, R S Marg , Malad (E) , Mumbai- 400 097.  
**Unaudited Financial Results for the Quarter & Nine Months ended December 31, 2013**

(₹ In Lacs)

Sr. No.	Particulars	3 Months ended 31.12.2013	Preceding 3 Months ended 30.09.2013	Corresponding 3 Months ended 31.12.2012	Corresponding 6 Months ended 31.12.2013	Corresponding 6 Months ended 31.12.2012	Year to date figures as on 31.03.2013
		Un-Audited			Un-Audited		Audited
1	<b>Income from Operations</b>						
	a) Net Sales/Income from Operations	964.16	325.72	-	2,248.12	-	-
	b) Other Operating Income	-	-	-	-	-	-
	<b>Total Income from Operations (Net)</b>	<b>964.16</b>	<b>325.72</b>	<b>-</b>	<b>2,248.12</b>	<b>-</b>	<b>-</b>
2	<b>Expenditure</b>						
	(a) Cost of Material Consumed	-	-	-	-	-	-
	(b) Purchases of Stock-in-trade	944.23	320.07	-	2,208.93	-	-
	(c) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	-	-	-	-	-	-
	(d) Employees Benefit Expenses	1.62	1.48	1.12	5.05	2.72	3.75
	(e) Depreciation & Amortization Expenses	-	-	-	-	-	-
	(f) Exchange & Depository Expenses	-	-	0.87	-	2.85	-
	(g) Other Expenditure	3.75	2.42	1.56	7.67	5.44	4.51
	<b>Total Expenses</b>	<b>949.60</b>	<b>323.97</b>	<b>3.55</b>	<b>2,221.65</b>	<b>11.01</b>	<b>8.26</b>
3	<b>Profit/(Loss) from Operations before other Income, finance cost and exceptional Expenses (1-2)</b>	<b>14.56</b>	<b>1.75</b>	<b>(3.55)</b>	<b>26.47</b>	<b>(11.01)</b>	<b>(8.26)</b>
4	Other Income/(Loss)	22.62	9.84	8.68	32.46	25.18	28.64
5	<b>Profit/(Loss) from ordinary activities before finance costs and exceptional items (3+4)</b>	<b>37.18</b>	<b>11.59</b>	<b>5.13</b>	<b>58.93</b>	<b>14.17</b>	<b>20.38</b>
6	Finance Costs	-	-	-	-	-	-
7	<b>Profit/(Loss) from ordinary activities after finance cost but before exceptional items (3+4)</b>	<b>37.18</b>	<b>11.59</b>	<b>5.13</b>	<b>58.93</b>	<b>14.17</b>	<b>20.38</b>
8	Exceptional Items	-	-	-	-	-	-
9	<b>Profit(+)/Loss(-) from ordinary activities before Tax (7-8)</b>	<b>37.18</b>	<b>11.59</b>	<b>5.13</b>	<b>58.93</b>	<b>14.17</b>	<b>20.38</b>
10	Tax Expenses	-	-	-	-	-	6.30
11	<b>Net Profit (+)/Loss(-) from ordinary activities after tax (9-10)</b>	<b>37.18</b>	<b>11.59</b>	<b>5.13</b>	<b>58.93</b>	<b>14.17</b>	<b>14.09</b>
12	Extra Ordinary Items (Net of Tax Expense of Rs. Lac)	-	-	-	-	-	-
13	<b>Net Profit (+)/Loss(-) for the period (11-12)</b>	<b>37.18</b>	<b>11.59</b>	<b>5.13</b>	<b>58.93</b>	<b>14.17</b>	<b>14.09</b>
14	<b>Net Profit (+)/Loss(-) after tax, minority interest and Share of Profit / (Loss) of Associates (13-14-15)</b>	<b>37.18</b>	<b>11.59</b>	<b>5.13</b>	<b>58.93</b>	<b>14.17</b>	<b>14.09</b>
15	Paid-up Equity Share Capital (Face Value of Rs. 1/- each)	362.40	362.40	233.60	362.40	233.60	307.40
16	Reserves excluding revaluation Reserves as per last Balance Sheet	-	-	-	-	-	968.27
17	<b>Earning Per Share (before extra-ordinary items) of Rs. 1/- each [Previous Quarters, Rs. 10/- each] (not annualized)</b>						
(i)	a) Basic	0.10	0.32	0.22	0.16	0.61	0.46
	b) Diluted	0.10	0.32	0.22	0.16	0.61	0.46
17	<b>Earning Per Share (after extra-ordinary items) of Rs. 1/- each [Previous Quarters, Rs. 10/- each] (not annualized)</b>						
(ii)	a) Basic	0.10	0.32	0.22	0.16	0.61	0.46
	b) Diluted	0.10	0.32	0.22	0.16	0.61	0.46
<b>A</b>	<b>PARTICULARS OF SHAREHOLDING</b>						
	Public Shareholding						
	- Number of Shares	36,215,000	3,621,500	2,333,500	36,215,000	2,333,500	3,071,500
	- Percentage of Share Holding	99.93	99.93	99.89	99.93	99.89	99.92
18	Promoter and Promoter Group Shareholding						
	a) Pledged/Encumbered	-	-	-	-	-	-
	- Number of Shares	-	-	-	-	-	-
	- Percentage of Shares (as a % of the total Shareholding of Promoter and Promoter Group)	-	-	-	-	-	-
	- Percentage of Shares (as a % of the total Share Capital of the Company)	-	-	-	-	-	-
	b) None-Encumbered						
	- Number of Shares	25,000	2,500	2,500	25,000	2,500	2,500
	- Percentage of Shares (as a % of the total Shareholding of Promoter and Promoter Group)	100.00	100.00	100.00	100.00	100.00	100.00
	- Percentage of Shares (as a % of the total Share Capital of the Company)	0.07	0.07	0.11	0.07	0.11	0.08
<b>B</b>	<b>INVESTOR COMPLAINTS</b>						
	Pending at the beginning of the Quarter	Nil	Disposed during the Quarter				Nil
	Received during the Quarter	Nil	Remaining Unresolved at the end of Quarter				Nil

**Notes :**

1. Segmental Report for the Quarter as per AS-17 of ICAI is not applicable for the Quarter.
2. Above results were reviewed by Audit Committee taken on record in Board Meeting held on January 28, 2014.
3. Provision for Taxation will be made at the end of the Financial Year.
4. The Statutory Auditors of the Company have carried out "Limited Review" of the above Financial Results.
5. During the Quarter, Face Value of Equity Shares have been sub-divided from Rs. 10/- to Rs. 1/-.
6. There was a change in situation of Registered Office within City limit during the Quarter.

**For Lifeline Drugs & Pharma Limited**  
 Sd/-  
**Alok Behera**  
 Managing Director

Place : Mumbai  
 Date : January 28, 2014